SCHEMBL29522483

SCHEMBL29522483

CO[C@H]1CC[C@@H](N2CC(=O)Nc3ncc(-c4ccc(-c5nnc[nH]5)nc4C)nc32)CC1

nearest known ligand 0.75

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MTOR P42345 19/20 0.75
RPTOR Q8N122 17/20 0.75
MLST8 Q9BVC4 17/20 0.75
PIK3CA P42336 8/20 0.55
CSF1R P07333 2/20 0.40
PRKDC P78527 1/20 0.40
PDE3B Q13370 1/20 0.40
PDE3A Q14432 1/20 0.40
PIK3CD O00329 1/20 0.35
FLT4 P35916 1/20 0.35
PIK3CB P42338 1/20 0.35
PIK3CG P48736 1/20 0.35
KCNH2 Q12809 1/20 0.35
PIK3C3 Q8NEB9 1/20 0.35
PI4KB Q9UBF8 1/20 0.35
IDH1 O75874 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL135767 1.00 MTOR (0.75) MTORRPTORMLST8PIK3CACSF1R
SCHEMBL154745 1.00 MTOR (0.75) MTORRPTORMLST8PIK3CACSF1R
SCHEMBL154746 1.00 MTOR (0.75) MTORRPTORMLST8PIK3CACSF1R
SCHEMBL151975 0.95 MTOR (0.69) MTORRPTORMLST8PIK3CACSF1R
SCHEMBL155833 0.95 MTOR (0.69) MTORRPTORMLST8PIK3CACSF1R
SCHEMBL17923245 0.95 MTOR (0.69) MTORRPTORMLST8PIK3CACSF1R
SCHEMBL154325 0.95 MTOR (0.69) MTORRPTORMLST8PIK3CACSF1R
SCHEMBL157649 0.95 MTOR (0.69) MTORRPTORMLST8PIK3CACSF1R
SCHEMBL138231 0.91 MTOR (0.61) MTORRPTORMLST8PIK3CACSF1R
SCHEMBL10239838 0.85 MTOR (0.55) MTORRPTORMLST8PIK3CACSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230119470-A1 PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY SIGNAL PHARM LLC (US) 2023-04-20 US disclosed
US-11292796-B2 Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors SIGNAL PHARMACEUTICALS, LLC (US) 2022-04-05 US disclosed
CN-106117213-B Heteroaryl compounds and methods for their synthesis and purification 西格诺药品有限公司 2022-03-18 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230119470-A1 PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY MTOR, RICTOR, RPTOR MTOR 1/4885RPTOR 3/4885MLST8 81/4885
US-11292796-B2 Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors MTOR, RICTOR, RPTOR MTOR 1/4885RPTOR 3/4885MLST8 253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.